AstraZeneca (AZN): news on Monday 5 October 2026

The 11 stories

Each headline's own score, strongest first. Links go to the publisher.

• +10.0 AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials Pharmafile
  Positive phase 3 COPD data with up to 34% fewer exacerbations.
• +9.7 FDA Speeds Review of AstraZeneca Bladder Cancer Regimen MyChesCo
  FDA accelerated review of bladder cancer regimen is a clear positive.
• −9.2 BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’ Stocktwits
  Heart drug trial with Ionis missed its goal, a clear setback.
• +7.5 AstraZeneca Gets CDSCO Panel Nod to Import, Market Camizestrant for Breast Cancer Medical Dialogues
  Indian panel backs camizestrant import and marketing, supporting approval prospects.
• +6.3 Summit, AstraZeneca and Daiichi Sankyo Plan Phase III Trial in Triple-Negative Breast Cancer Medical Dialogues
  Planned phase III trial in breast cancer with partners shows pipeline progress.
• +5.8 DTI, AstraZeneca deepen Philippines clinical Daily Tribune
  Partnership to expand clinical research in the Philippines is a modest positive.
• +5.5 DTI, AstraZeneca push PH as clinical research, life sciences hub InsiderPH
  Same DTI partnership to build life sciences hub; mildly positive.
• −2.0 AstraZeneca Stock Drops 1.35%, Golden Cross: Explained JournalArta
  Share price dip of 1.35%, with a technical signal mentioned.
• −1.7 AstraZeneca stock falls 1.35 percent as cancer trial expands AD HOC NEWS
  Shares fell 1.35% though the cancer trial expanded.
• −1.3 AstraZeneca-Bristol Myers’ $400B Merger Buzz Cools After Report Denies Talks – ‘There Never Was A Deal To Be ​Done’ Stocktwits
  Merger buzz cooled after report denied talks.
• 0.0 AstraZeneca admits new shares. AstraZeneca stock costs EUR 139.63 versus EUR 139.63 AD HOC NEWS
  Routine new share admission and price quote, nothing about prospects.